“Viltolarsen was negative in a standard battery of in vitro (Ames, chromosomal aberration in CHL cells) and in vivo (mouse micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
Carcinogenicity
Not conducted pre-approval (agreed); rasH2 mouse and 2-year rat studies as PMRs
“Carcinogenicity studies of viltolarsen were not submitted to the NDA, as agreed to by the Division.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Reproductive & developmental
Male mouse fertility study only (no effects); EFD/PPND waived for male population; juvenile mouse study
“Embryofetal development and pre- and postnatal development studies were not conducted, as agreed to by the Division, because of the intended patient population, which is almost exclusively male.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Safety pharmacology
Dedicated single-dose studies: rat CNS (FOB), monkey CV/respiratory, in vitro hERG; no effects
“Dedicated single dose studies in rat (CNS) and monkey (cardiovascular and respiratory) did not indicate drug effects on safety pharmacology endpoints, and there was no effect on QT prolongation in CHO cell cultures exposed to up to 3 mg/mL vitolarsen.”
✓ VerifiedFDA pharmacology/toxicology review, p. 47Source ↗